Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized partially blinded study of MenABCWY and MenACWY-7B meningococcal vaccines in healthy infants
MOH_2023-09-07_012919Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Meningococcal ABCYW vaccine, MenACWY-7B, meningococcal group B vaccine and meningococcal A conjugate vaccine in meningococcal disease (4 arms), sponsored by GSK. Primary endpoints: Safety and tolerability and Immunogenicity. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
Meningococcal ABCYW vaccineMenACWY-7Bmeningococcal group B vaccinemeningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on MOH_2023-09-07_012919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-07_012919.